- GSK (NYSE: GSK) is acquiring Nuvalent (NASDAQ: NUVL) for $10.60 billion, strategically expanding its oncology drug pipeline.
- The $10.60 billion acquisition deal is under investigation by a law firm, scrutinizing Nuvalent’s board’s fiduciary duty to shareholders.
Nuvalent is a leading biotechnology company that develops targeted therapies for cancer treatment. The company focuses on creating innovative drugs that address limitations in current treatments for cancers driven by specific gene mutations, such as ROS1 and ALK. Its portfolio of potential best-in-class kinase inhibitors has made it a notable acquisition candidate in the competitive pharmaceutical industry.
Pharmaceutical giant GSK is acquiring Nuvalent in a $10.60 billion all-cash transaction. GSK will pay $124.00 per share, which represented a 40% premium over Nuvalent’s prior closing price. This strategic acquisition is a significant move by GSK to expand its oncology portfolio, with a specific focus on advanced treatments for lung cancer.
In response to the acquisition news, an analyst from Stifel Nicolaus downgraded Nuvalent to a “Hold” rating from “Buy.” The analyst also set a price target of $124.00, which precisely matches the price per share offered by GSK. This indicates the analyst believes Nuvalent’s stock price has very little upside potential remaining.
The market reacted strongly to the acquisition announcement, with Nuvalent’s stock price surging 39.54% to $123.48. The stock reached a new 52-week high of $123.57 on a significant trading volume of approximately 44.55 million shares. The agreed-upon acquisition price is clearly the primary driver behind the stock’s current trading level near its new target.
However, the acquisition deal is currently facing scrutiny. As highlighted by Business Wire, the prominent law firm Halper Sadeh LLC has initiated an investigation into the sale. The firm is reviewing whether Nuvalent’s board of directors fulfilled its fiduciary duty, which is its legal obligation to secure the best possible price for its shareholders.
